Replies to post #221718 on Biotech Values

[DewDiligence]

INO—…what [is] the point of producing therapeutic proteins and antibodies endogenously? Why bother, especially for therapeutic proteins?

As far as I can tell, the premise is the potential availability of dMAbs in parts of the world where conventionally produced antibody drugs are unaffordable.